Home > Publications Database > BACE1 regulates sleep–wake cycle through both enzymatic and non–enzymatic actions > print

001     282938
005     20260309111317.0
024 7 _ |a 10.1038/s44319-025-00604-4
|2 doi
024 7 _ |a 1469-221X
|2 ISSN
024 7 _ |a 1469-3178
|2 ISSN
037 _ _ |a DZNE-2025-01399
082 _ _ |a 570
100 1 _ |a Heininger, Hannah
|b 0
245 _ _ |a BACE1 regulates sleep–wake cycle through both enzymatic and non–enzymatic actions
260 _ _ |a [London]
|c 2026
|b Nature Publishing Group UK
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1768231604_9863
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The β-secretase BACE1 has become a prime target in Alzheimer’s disease (AD) therapy, because it drives the production of pathogenic amyloid β peptides. However, clinical trials with BACE1-targeting drugs were halted due to adverse effects on cognitive performance. We propose here that cognitive impairment by BACE1 inhibitors may be a corollary of a higher function of BACE1 related to proper sleep regulation. To address non-enzymatic effects of BACE1 on ion channels likely involved in the sleep-wake cycle, we analyze sleep patterns in both BACE1-KO mice and a newly generated transgenic line expressing a proteolysis-deficient BACE1 variant (BACE1-KI). We find that BACE1-KI and BACE1-KO mice display common and distinct sleep-wake disturbances. Compared with their respective wild-type littermates, both mutant lines sleep less during the light phase (when they preferentially rest). Furthermore, transition rates between wake and sleep states are altered, as are sleep spindles and EEG power spectra mainly in the gamma range. Thus, a better understanding of how BACE1 interferes with sleep-modulated behaviors is needed if clinical trials with BACE1-targeted inhibitors are to resume.
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, Journals: pub.dzne.de
700 1 _ |a Feng, Xiao
|0 P:(DE-2719)9000546
|b 1
|u dzne
700 1 _ |a Altunkaya, Alp
|b 2
700 1 _ |a Zheng, Fang
|0 0000-0002-5699-8063
|b 3
700 1 _ |a Stockinger, Florian
|0 0009-0002-9101-7491
|b 4
700 1 _ |a Wefers, Benedikt
|0 P:(DE-2719)2810988
|b 5
|u dzne
700 1 _ |a Müller, Stephan A
|0 P:(DE-2719)2810938
|b 6
700 1 _ |a Giesbertz, Pieter
|0 P:(DE-2719)9001718
|b 7
700 1 _ |a Tschirner, Sarah
|0 P:(DE-2719)9000794
|b 8
|u dzne
700 1 _ |a Shqau, Dorina
|0 0009-0001-5047-4410
|b 9
700 1 _ |a Adelsberger, Helmuth
|b 10
700 1 _ |a Ponomarenko, Alexey
|b 11
700 1 _ |a Fenzl, Thomas
|0 0000-0002-0132-9591
|b 12
700 1 _ |a Alzheimer, Christian
|b 13
700 1 _ |a Lichtenthaler, Stefan F
|0 P:(DE-2719)2181459
|b 14
|e Last author
700 1 _ |a Huth, Tobias
|0 0000-0002-6414-8923
|b 15
773 _ _ |a 10.1038/s44319-025-00604-4
|0 PERI:(DE-600)2025376-X
|p 50 - 68
|t EMBO reports
|v 27
|y 2026
|x 1469-221X
787 0 _ |a Müller, Stephan A et.al.
|d PRoteomics IDEntifications Database, 2025
|i RelatedTo
|0 DZNE-2025-01398
|r
|t Dataset: Secretome and lysate proteomics of primary murine neurons with inactive BACE1
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/282938/files/DZNE-2025-01399.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/282938/files/DZNE-2025-01399.pdf?subformat=pdfa
876 7 _ |a #758
|c 6717.15
|e APC
|d 2026-03-09
|j DEAL
|9 2026-02-18
909 C O |o oai:pub.dzne.de:282938
|p openaire
|p open_access
|p OpenAPC
|p driver
|p VDB
|p openCost
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)9000546
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)2810988
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)2810938
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)9001718
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 8
|6 P:(DE-2719)9000794
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 9
|6 0009-0001-5047-4410
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 14
|6 P:(DE-2719)2181459
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-12
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2024-12-12
|w ger
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b EMBO REP : 2022
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-04-09T14:01:41Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-04-09T14:01:41Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-12
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-12
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-12
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review, Double anonymous peer review
|d 2024-04-09T14:01:41Z
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-12
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b EMBO REP : 2022
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-12
915 p c |a APC keys set
|2 APC
|0 PC:(DE-HGF)0000
915 p c |a Local Funding
|2 APC
|0 PC:(DE-HGF)0001
915 p c |a DFG OA Publikationskosten
|2 APC
|0 PC:(DE-HGF)0002
915 p c |a DOAJ Journal
|2 APC
|0 PC:(DE-HGF)0003
920 1 _ |0 I:(DE-2719)1110006
|k AG Lichtenthaler
|l Neuroproteomics
|x 0
920 1 _ |0 I:(DE-2719)1140001
|k AG Wurst
|l Genome Engineering
|x 1
980 1 _ |a FullTexts
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1110006
980 _ _ |a I:(DE-2719)1140001
980 _ _ |a APC

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21